Magnesium Balance in Chronic Kidney Disease: Mineral Metabolism, Immunosuppressive Therapies and Sodium-Glucose Cotransporter 2 Inhibitors
Por:
Díaz-Tocados, JM, Lloret, MJ, Domínguez-Coral, JD, Aranda, APT, de Arizón, LF, Jiménez, EM, Bover, J, Valdivielso, JM and Rodríguez-Ortiz, ME
Publicada:
13 jun 2025
Ahead of Print:
13 jun 2025
Resumen:
It is now widely recognized that maintaining magnesium (Mg) homeostasis is critical for health, especially in the context of chronic kidney disease (CKD). Patients with CKD commonly develop hyperphosphatemia and secondary hyperparathyroidism, which are controlled by therapies targeting intestinal phosphate absorption and circulating calcium levels or by modulating parathyroid calcium sensing. Notably, Mg supplementation may provide dual benefits by promoting bone formation and maintaining normal mineralization with slightly elevated serum levels. Importantly, low Mg levels are associated with mortality risk in CKD, highlighting the importance of maintaining adequate serum Mg levels in these patients. Particularly, kidney transplant (KT) patients have lower circulating Mg levels, likely due to interactions with immunosuppressive treatments. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown survival benefits in CKD and increased serum Mg levels, suggesting that Mg regulation may contribute to these outcomes. Overall, Mg plays a key role in CKD-associated mineral and bone disorders (CKD-MBD). Thus, understanding the mechanisms underlying the alteration of Mg homeostasis in CKD could improve clinical outcomes. This review summarizes the basic and clinical studies demonstrating (1) the key actions of Mg in CKD-MBD, including secondary hyperparathyroidism and bone abnormalities; (2) the distinctive profile of KT patients for Mg homeostasis; and (3) the interaction between commonly used drugs, such as SGLT2 inhibitors or immunosuppressive treatments, and Mg metabolism, providing a broad understanding of both the key role of Mg in the context of CKD and the treatments that should be considered to manage Mg levels in CKD patients.
Filiaciones:
Díaz-Tocados, JM:
Biomed Res Inst Lleida IRBLleida, Vasc & Renal Translat Res Grp, Lleida 25198, Spain
Carlos III Health Inst ISCIII, Cooperat Res Network Oriented Hlth Outcomes RICORS, Madrid 28029, Spain
Lloret, MJ:
Fundacio Puigvert, Nephrol Dept, Barcelona 08025, Spain
Univ Autonoma Barcelona, Inst Recerca St Pau IR St Pau, Dept Med, Barcelona 08041, Spain
Domínguez-Coral, JD:
Biomed Res Inst Lleida IRBLleida, Vasc & Renal Translat Res Grp, Lleida 25198, Spain
Carlos III Health Inst ISCIII, Cooperat Res Network Oriented Hlth Outcomes RICORS, Madrid 28029, Spain
Aranda, APT:
Fundacio Puigvert, Nephrol Dept, Barcelona 08025, Spain
de Arizón, LF:
Fundacio Puigvert, Nephrol Dept, Barcelona 08025, Spain
Univ Autonoma Barcelona, Inst Recerca St Pau IR St Pau, Dept Med, Barcelona 08041, Spain
Jiménez, EM:
Carlos III Health Inst ISCIII, Cooperat Res Network Oriented Hlth Outcomes RICORS, Madrid 28029, Spain
Germans Trias & Pujol Univ Hosp, Nephrol Dept, REMAR IGTP Grp, Badalona 08916, Spain
:
Carlos III Health Inst ISCIII, Cooperat Res Network Oriented Hlth Outcomes RICORS, Madrid 28029, Spain
Germans Trias & Pujol Univ Hosp, Nephrol Dept, REMAR IGTP Grp, Badalona 08916, Spain
Valdivielso, JM:
Biomed Res Inst Lleida IRBLleida, Vasc & Renal Translat Res Grp, Lleida 25198, Spain
Carlos III Health Inst ISCIII, Cooperat Res Network Oriented Hlth Outcomes RICORS, Madrid 28029, Spain
Rodríguez-Ortiz, ME:
Carlos III Health Inst ISCIII, Cooperat Res Network Oriented Hlth Outcomes RICORS, Madrid 28029, Spain
Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomed Cordoba IMIBIC, Nephrol Dept,Nephrol & Cell Damage Chron Inflammat, Cordoba 14004, Spain
Green Submitted, gold
|